Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1

Abstract

Abstract Imatinib mesylate seemed to inhibit development of cutaneous neurofibromas (c‐NFs) and promote growth of pre‐existing c‐NFs in our neurofibromatosis type 1 case. This report potentially provides new findings in the effects of imatinib mesylate.

Keywords

• cutaneous neurofibroma
• imatinib mesylate
• neurofibromatosis type 1
• NF1
• paradoxical reaction
• RASopathy